Lutetium (177Lu) Vipivotide Tetraxetan CAS 1703749-62-5

Introduction：Basic information about Lutetium (177Lu) Vipivotide Tetraxetan CAS 1703749-62-5, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Lutetium (177Lu) Vipivotide Tetraxetan Basic information

• Product Name: Lutetium (177Lu) Vipivotide Tetraxetan
• Synonyms: Vipivotide tetraxetan Lu-177;Lutetate(3-)-177Lu, [N2-[[[(1S)-1,3-dicarboxypropyl]amino]carbonyl]-N6-[3-(2-naphthalenyl)-N-[[trans-4-[[[2-[4,7,10-tris[(carboxy-κO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]acetyl-κO]amino]methyl]cyclohexyl]carbonyl]-L-alanyl]-L-lysinato(6-)]-, hydrogen (1:3);Lutetium (177Lu) Vipivotide Tetraxetan
• CAS: 1703749-62-5
• MW: 0
• Mol File: Mol File

Lutetium (177Lu) Vipivotide Tetraxetan Usage And Synthesis

Uses

177Lu-PSMA-617 (trade name: Pluvicto) is a radiopharmaceutical used to treat prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). This drug is a peptide radiopharmaceutical that combines a PSMA-targeting ligand with the radioisotope lutetium-177, delivering radiation therapy by binding to PSMA-positive cancer cells.

Description

177Lu-PSMA-617 (trade name: Pluvicto) is a radiopharmaceutical used to treat prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). This drug is a peptide radiopharmaceutical that combines a PSMA-targeting ligand and a radioisotope, Lutetium-177, to deliver radiotherapy by binding to PSMA-positive cancer cells.

Mechanism of action

PSMA is a protein that is overexpressed on the surface of prostate cancer cells, making it an ideal target for radiotherapy. Lutetium (177Lu) Vipivotide Tetraxetan binds to PSMA with high affinity, delivering the radioisotope directly to cancer cells, thereby reducing damage to surrounding normal tissue.